#USA #San Diego #Nivolumab #HUYABIO #HBI-8000

HUYABIO International's Innovative Treatment for Advanced Melanoma

In a major breakthrough, HUYABIO International announced the results of a Phase 3 clinical trial demonstrating that their oral medication HBI-8000, when used in conjunction with the intravenous drug nivolumab, results in a 27% reduction in the risk of disease progression or death for patients with advanced melanoma.

This study revealed that the combination treatment led to a statistically significant and meaningful improvement in progression-free survival (PFS), with the median survival rate reaching 11.7 months for patients receiving the HBI-8000-nivolumab tandem, compared to just 7.4 months for those on nivolumab alone. These findings were shared during a session at the European Society for Medical Oncology (ESMO) Congress 2026, where Dr. Nikhil Khushalani from Moffitt Cancer Center presented the data.

The advancements presented by HUYABIO come at a crucial time, as there is a pressing need for novel treatments that provide efficacy while maintaining safety and convenience. The dual use of an oral agent like HBI-8000, administered twice weekly along with an intravenous infusion of nivolumab, may present an encouraging alternative to traditional immune checkpoint inhibitors which often come with higher risks of adverse reactions.

HBI-8000 is a selective Class I histone deacetylase (HDAC) inhibitor, redesigned to enhance the immune response to cancer by epigenetically altering the tumor microenvironment. Research has suggested that HBI-8000 transforms tumors considered 'cold' into 'hot' ones, thereby improving the efficacy of existing therapies including PD-1 checkpoint inhibitors.

Dr. Mireille Gillings, Founder and CEO of HUYABIO, expressed excitement about the data, stating that this innovative combination could redefine treatment standards for advanced melanoma, extending patients' progression-free survival while also minimizing toxicity effects typically associated with dual immune checkpoint agents.

The trial, which encompassed 404 patients across 15 nations, indicated that patients receiving HBI-8000 along with nivolumab experienced a PFS hazard ratio of 0.73, suggesting a clear advantage. Notably, adverse events linked to the combination therapy reflected the expected safety profiles and did not include heightened incidences of significant immune-related complications often arising from dual checkpoint inhibitors.

According to the results, while the combination therapy did see higher rates of treatment-related adverse events, these were well-managed, marking a favorable safety profile overall. Patients participating in the combination group showed common side effects like diarrhea, nausea, and fatigue, but the incidence rates were deemed manageable by medical professionals. Importantly, the data did not reflect an uptick in permanent complications such as adrenal insufficiency or hypophysitis, further confirming the treatment's safety.

As HUYABIO International continues to seek FDA approval, the company is poised to engage with commercial partners to expedite the accessibility of this potentially game-changing therapy to patients worldwide. A full manuscript detailing the complete findings of this trial will soon be submitted for peer review, indicating the company's commitment to transparency and scientific integrity.

Overall, HUYABIO's data presents a hopeful outlook for melanoma patients, indicating that with ongoing research and potential FDA endorsement, HBI-8000 could soon turn into a new cornerstone for frontline treatment in combating advanced melanoma, aiming towards a future where patient outcomes improve significantly and toxicity is minimized.